Battery circularity, the recycling, reuse, and repurposing of batteries, has become the fastest-growing area of battery patenting, and its landscape is a map of the coming competition over critical minerals. According to a joint study by the European Patent Office and the International Energy Agency, international patent families related to battery circularity grew at an average of 42 percent per year from 2017 to 2023, compared with 16 percent for rechargeable battery manufacturing overall and 2 percent across all technical fields.¹ Over the decade the number of these families rose roughly sevenfold.¹ The driver is structural: more than one in four cars sold globally in 2025 was electric, and around 1.2 million electric-vehicle batteries could reach end of life in 2030, rising to 14 million by 2040, so managing and reclaiming that volume is both an environmental necessity and a supply-chain strategy.¹

The landscape is geographically concentrated and shifting quickly. Asian applicants accounted for 63 percent of battery-circularity patent families in 2023, and China's share rose from 5 percent in 2013 to 29 percent in 2023, with Brunp, the recycling subsidiary of a major battery maker, overtaking established Japanese and Korean firms to become the most active filer.¹ European companies and research institutes account for roughly 20 percent of families, with particular strength in the collection and pre-processing of used batteries and in chemical transformation to recover raw materials, reflecting Europe's current role more as a battery user than a producer.¹ An independent count across the Cypris corpus of more than 500 million patents and scientific papers reproduces the same picture: China holds roughly two-thirds of the recycling-specific family set, well ahead of the United States, Germany, South Korea, and Japan, and Brunp is the single most active assignee, ahead of chemical and battery-materials firms such as BASF and Sumitomo Metal Mining. The strategic significance is large: energy storage now represents about 40 percent of all energy-related patenting and is heading toward half, and recycled materials could meet more than a fifth of demand for lithium, nickel, and cobalt by 2040.¹

The technology landscape divides into distinct stages, each a region of patenting. A peer-reviewed patent-network analysis of lithium-ion battery recycling covering 1990 to 2024 finds activity rising steeply since around 2020, with China leading and international collaboration remaining limited,² and bibliometric analysis of the field documents the same long-run acceleration in recycling research and patenting.³ Across the Cypris corpus, hydrometallurgy is the most patented chemical-recovery route, well ahead of pyrometallurgy, while direct recycling and cathode regeneration remain comparatively nascent; a large, separate cluster covers collection, pre-processing, and separation, the earlier stage where Europe is comparatively strong. Metal recovery and cathode regeneration are where much of the chemical innovation and value concentrate, with key work focused on improving leaching efficiency, developing purification methods, and relithiation strategies that restore spent cathode materials. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the current frontier is even more active than the figures show.

Where the battery-circularity white space is

Direct cathode regeneration. Restoring spent cathode material directly, rather than breaking it down to metals, is a higher-value route that remains comparatively nascent in the patent record, leaving room for defensible positions.²

Efficient metal recovery. Improving leaching efficiency and purification for lithium, nickel, and cobalt is where much chemical innovation concentrates and where recovery economics are decided.²

Collection and pre-processing. Sorting, dismantling, and safe handling, including remote-handling technologies, are an earlier stage where activity is comparatively less crowded and where European applicants are relatively strong.¹

Reuse and repurposing. Second-life applications for batteries, distinct from material recovery, are a separate and growing layer.

Design for recyclability. Battery designs that ease disassembly and recovery link circularity back to manufacturing and are an emerging cross-over area.

How AI-powered landscape and white space analysis helps

Resolving a fast-growing landscape across stages, chemistries, and geographies requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by recovery route and processing stage across varied terminology, attribution that normalizes filers to canonical entities and tracks shifting leadership, and continuous monitoring that keeps pace with a field growing far faster than average. Because circularity advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier is moving.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-growing energy fields such as battery circularity across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by recovery route, hydrometallurgy, direct regeneration, separation, and pyrometallurgy, and by processing stage, and normalizes filers to canonical entities, so a team can resolve which routes and stages are crowded and which remain open as white space, and can track shifting leadership as new entrants rise. Semantic search across patents and scientific literature connects filings to the underlying materials and process research, which is where circularity advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is battery-recycling patenting growing? Battery-recycling patenting is growing very fast. According to the EPO and IEA, international patent families in battery circularity grew at an average of 42 percent per year from 2017 to 2023, versus 16 percent for battery manufacturing and 2 percent across all technical fields, roughly a sevenfold increase over the decade. It is now growing faster than battery patenting in general.

Who leads in battery-circularity patents? Asian applicants held 63 percent of battery-circularity patent families in 2023. China's share rose from 5 percent in 2013 to 29 percent in 2023, and Brunp, a major battery maker's recycling subsidiary, overtook established Japanese and Korean firms as the most active filer. European companies and research institutes hold roughly 20 percent, with strength in collection and pre-processing. An independent Cypris-corpus count reproduces China's roughly two-thirds share and Brunp's lead.

What technologies does the battery-recycling landscape cover? The battery-recycling landscape covers collection, sorting, and dismantling; mechanical processing; and metal recovery and cathode regeneration. Analysis of the patent record finds hydrometallurgy the most patented chemical-recovery route, ahead of pyrometallurgy, with direct recycling still comparatively nascent. Innovation concentrates on leaching efficiency, purification, and relithiation.

Why is battery circularity strategically important? Battery circularity is strategically important because it is a secondary supply of critical minerals. Around 1.2 million electric-vehicle batteries could reach end of life in 2030 and 14 million by 2040, and recycled materials could meet more than a fifth of lithium, nickel, and cobalt demand by 2040. This links recycling to supply-chain security and energy security.

Where is the white space in battery recycling? The white space in battery recycling includes direct cathode regeneration, efficient metal recovery and purification, collection and pre-processing including remote handling, reuse and repurposing for second-life applications, and design for recyclability. Metal recovery and cathode regeneration are where chemical innovation concentrates. The higher-value opportunities are in routes that improve recovery economics.

Why does battery-recycling analysis need scientific literature? Battery-recycling analysis needs scientific literature because process and materials advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use battery-recycling patent landscape analysis? Battery-recycling patent landscape analysis is used by R&D, innovation, IP, and strategy teams at battery makers, recyclers, automotive and energy companies, materials developers, and their partners, as well as investors and policymakers. It informs where to invest, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

How do you keep a battery-recycling landscape current? Keeping a battery-recycling landscape current requires continuous monitoring, because the field is growing far faster than average, leadership is shifting quickly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track a defined route and flag new patents and papers as they publish.

Endnotes

1. International Energy Agency & European Patent Office (2026). Battery circularity: innovation trends for a future source of critical materials. IEA, Paris. https://www.iea.org/reports/battery-circularity
2. von Delft, S., Schlehuber, S., & Hemmelder, A. (2025). Uncovering collaboration and knowledge areas in lithium-ion battery recycling. EES Batteries. https://doi.org/10.1039/d5eb00056d
3. Li, Y., Guo, Y., Guan, J., Zhang, X., & Lou, X. (2022). Global trend for waste lithium-ion battery recycling from 1984 to 2021: a bibliometric analysis. Minerals, 12(12), 1514. https://doi.org/10.3390/min12121514

‍

AAV gene therapy has crossed into commercial reality, and its patent landscape is distinctive because an AAV therapy is a modular product whose parts are patented separately. An adeno-associated virus vector delivers a therapeutic gene by packaging it inside an engineered protein shell, the capsid, whose surface engages target-cell receptors and whose fate through endocytosis, endosomal escape, and nuclear import determines where the therapy goes and how the immune system responds to it.¹ The intellectual property divides across distinct regions, each a distinct area of patenting: the capsid, spanning natural serotypes and, increasingly, engineered capsids produced by directed evolution, structure-guided design, and machine-learning-guided design;²,³,⁴,⁵ the strategies that address immunogenicity, because pre-existing neutralizing antibodies exclude many patients and the immune response generally prevents redosing;⁶,⁷ the transgene expression cassette, including the promoter and regulatory elements that control where and how strongly the gene is expressed; and the manufacturing process, where empty-capsid content, host-cell productivity, and the ratio of full to empty particles remain challenges at commercial scale.⁸ Because a therapy depends on several of these layers and they are often held by different owners, freedom-to-operate for an AAV product is a multi-layer, multi-owner analysis rather than a single clearance.

The competitive and legal environment has raised the stakes across every layer. Capsid engineering is the most active area of IP, with specialized platform companies developing next-generation capsids that target specific tissues such as the brain, muscle, and retina and that aim to evade pre-existing immunity, and licensing these platforms to larger developers.⁴,⁹ At the same time, foundational vector patents have been litigated, with the Federal Circuit deciding an appeal on core AAV vector claims in early 2026, so the boundaries of the foundational estate continue to be tested even as the field advances.¹⁰ The commercial ground is set by a broader wave of approved products: as of the 2024 review window, the US Food and Drug Administration had approved fourteen cellular and gene therapy products across the modality, of which the AAV-based Luxturna (voretigene neparvovec-rzyl) for RPE65-mediated inherited retinal dystrophy remains the AAV exemplar, first approved in the United States in 2017 and separately authorized in the European Union.⁴,¹¹,¹² Because applications publish about eighteen months after filing, the newest capsid and immune-evasion filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

The strategic question is where defensible, hard-to-design-around IP sits. Across the Cypris corpus of more than 500 million patents and scientific papers, the AAV capsid-variant set holds on the order of 12,966 families and grew from about 828 in 2020 to roughly 1,818 in 2024, with the most active assignees led by the University of Pennsylvania, Voyager Therapeutics, the University of Massachusetts, Genzyme, and UC San Diego, and the United States far ahead of China, France, and the United Kingdom on geography; 2025 and 2026 counts are partial because of the publication lag. The most active and high-value ground is in engineered capsids that both target a tissue precisely and evade pre-existing immunity, because these directly address the field's central limitations, and receptor-guided and machine-learning-guided capsid design are advancing quickly here.²,³,⁴,⁵ Redosing and immune-modulation technologies are a distinct and comparatively open layer,⁶,⁷ as are manufacturing methods that raise the full-to-empty ratio and lower cost,⁸ and expression-cassette designs that improve durability and tissue specificity.⁴,⁹ Reading the landscape by layer and by owner, and tracking both the patents and the underlying virology and immunology research, is what separates a workable position from a blocked one.

What creates FTO risk in AAV gene therapy

Capsid claims. These cover natural serotypes and engineered capsids from directed evolution, structure-guided, and machine-learning design, the most active and contested layer.²,³,⁴,⁵

Immunogenicity and redosing claims. These cover strategies to evade pre-existing antibodies and enable redosing, a distinct and high-value layer given the field's central limitation.⁶,⁷

Transgene and expression-cassette claims. These cover promoters, regulatory elements, and the engineered transgene that control expression, a separately owned layer.

Manufacturing and purification claims. These cover producer systems, full-to-empty separation, host-cell productivity, and purification, where practical, hard-to-design-around barriers concentrate.⁸

Tissue-targeting claims. These cover receptor-guided and tissue-specific delivery, which can independently constrain a competing program.⁹

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant capsid, immunogenicity, cassette, and manufacturing claims regardless of terminology, attribution that resolves the many owners and license chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because AAV advances appear in virology and immunology literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as AAV gene therapy across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, capsid, immunogenicity, expression cassette, and manufacturing, and normalizes developer, platform-specialist, and academic owners and their license chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new capsids and immune-evasion strategies emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for AAV gene therapy? Freedom-to-operate is hard for AAV gene therapy because a therapy is built from a capsid, an immune-evasion strategy, a transgene expression cassette, and a manufacturing process, each independently patentable and often held by different owners. The capsid layer alone is heavily engineered and contested. FTO must be assessed layer by layer across multiple estates.

Why is the capsid the key layer? The capsid is the key layer because it determines which tissues the therapy reaches and how the immune system responds, and it is where most engineering and patenting activity concentrates. Engineered capsids from directed evolution, structure-guided design, and machine learning aim to target tissues and evade immunity. That makes capsid IP the most active battleground.

What claim types create FTO risk in AAV therapy? Five claim types create FTO risk: capsid claims, immunogenicity and redosing claims, transgene and expression-cassette claims, manufacturing and purification claims, and tissue-targeting claims. Each covers a distinct layer and can be held by a different owner. The capsid and manufacturing layers are especially decisive.

Why do immunity and redosing matter so much? Immunity and redosing matter because pre-existing neutralizing antibodies exclude many patients from AAV therapy, and the immune response to a first dose generally prevents giving a second, so AAV is typically a single-dose modality. Technologies that evade pre-existing immunity or enable redosing address a central limitation. They are therefore a distinct, high-value layer.

Where is the white space in AAV gene therapy? The white space includes engineered capsids that target tissues and evade pre-existing immunity, redosing and immune-modulation technologies, manufacturing methods that raise the full-to-empty ratio, and expression-cassette designs that improve durability and specificity. Natural serotypes and liver-directed approaches are comparatively crowded. The durable, defensible value is in capsids, immune evasion, and manufacturing.

Why does AAV analysis need scientific literature? AAV analysis needs scientific literature because new capsids, immune-evasion strategies, and manufacturing advances appear in virology and immunology research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the AAV gene therapy patent landscape? Software for the AAV landscape should resolve developer, platform-specialist, and academic owners and license chains to canonical entities, cluster the capsid, immunogenicity, cassette, and manufacturing layers, search patents and scientific literature semantically, and monitor litigation and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need AAV patent landscape and FTO analysis? AAV patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at gene therapy and pharmaceutical companies, capsid-platform specialists, academic technology-transfer offices, and investors assessing gene therapy assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Hao, Y., & Xiang, J. (2023). Biophysical characterization of the AAV capsid through the viral transduction life cycle. Journal of Genetic Engineering and Biotechnology, 21. https://doi.org/10.1186/s43141-023-00518-5
2. Fakhiri, J., Becker, S., & Grimm, D. (2022). Fantastic AAV gene therapy vectors and how to find them: random diversification, rational design and machine learning. Pathogens, 11(7), 756. https://doi.org/10.3390/pathogens11070756
3. Qi, Y., et al. (2025). Artificial intelligence-based approaches for AAV vector engineering. Advanced Science, 12. https://doi.org/10.1002/advs.202411062
4. Gao, F., et al. (2024). AAV engineering and load strategy for tropism modification, immune evasion and enhanced transgene expression. International Journal of Nanomedicine, 19. https://doi.org/10.2147/ijn.s459905
5. Fu, W., et al. (2024). Machine-learning-guided directed evolution for AAV capsid engineering. Current Pharmaceutical Design. https://doi.org/10.2174/0113816128286593240226060318
6. Barnes, C., Scheideler, O., & Schaffer, D. (2019). Engineering the AAV capsid to evade immune responses. Current Opinion in Biotechnology, 60. https://doi.org/10.1016/j.copbio.2019.01.002
7. Meumann, N., Rodríguez-Márquez, E., & Büning, H. (2020). AAV capsid engineering in liver-directed gene therapy. Expert Opinion on Biological Therapy, 21(6). https://doi.org/10.1080/14712598.2021.1865303
8. Yoon, S., Lee, D., et al. (2024). Decoding cellular mechanism of rAAV and engineering host-cell factories. Biotechnology Advances, 72. https://doi.org/10.1016/j.biotechadv.2024.108322
9. Marković, I., et al. (2025). AAV gene therapy drug development and translation of engineered ocular and neurotropic capsids. Clinical and Translational Science, 18. https://doi.org/10.1111/cts.70428
10. RegenxBio Inc. v. Sarepta Therapeutics, Inc., No. 24-1408 (Fed. Cir. Feb. 20, 2026).
11. U.S. Food and Drug Administration. Approved cellular and gene therapy products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
12. U.S. Food and Drug Administration (2017). Luxturna (voretigene neparvovec-rzyl). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/luxturna

‍

Chemical intelligence unifies three data types that chemistry R&D depends on: patents, scientific literature, and chemical structure data. A question about a compound, a reaction, or a material rarely lives in one of these alone. The relevant disclosure may sit in a patent claim, a journal paper, or a structure database, and the connection between them is where the insight is.

Most tools address only one layer. Structure databases index compounds, patent databases index filings, and literature databases index papers, and researchers toggle between them manually. That fragmentation is slow and lossy: a compound found in one system is not automatically linked to the patents that claim it or the papers that characterize it.

In 2026, AI-powered chemical intelligence closes that gap. Semantic search and a structured model of the field retrieve across patents, papers, and structures together. This article defines chemical intelligence, explains why siloed search falls short, and describes how the AI-powered approach works.

What chemical intelligence covers

Chemical intelligence spans the full evidence base for a compound or material. It includes patents and published applications, peer-reviewed papers and preprints, chemical compound and structure data, synthesis and reaction information, and regulatory and commercial signals. The defining feature is unification: the same compound is connected across every source in which it appears.

This is broader than chemical patent search. Patent search answers what has been filed; chemical intelligence answers what is known about a compound or material across the literature, the patent record, and structure data at once, which is what R&D and IP teams in chemistry, materials, and pharmaceuticals actually need.

Why siloed chemical search falls short

Siloed search forces a researcher to run the same question three times, in three systems, with three query languages, and then reconcile the results by hand. Connections are missed because no single tool sees all the evidence. A compound identified in a structure database is not tied to the patents that claim it or the papers that report its properties.

Keyword search compounds the problem. In chemistry, the same compound or reaction is described under different names, notations, and terminology, so a keyword query misses filings and papers that use unexpected language. The volume of new chemistry filings and publications continues to rise, widening the gap between what a manual, siloed search finds and what actually exists.

How AI-powered chemical intelligence works

AI-powered chemical intelligence applies semantic search across a unified corpus of patents and scientific literature, retrieving disclosures by meaning rather than exact terms. This surfaces the papers and filings that describe a compound or reaction in different language, which keyword search overlooks.

An R&D ontology links the layers. Because an ontology is a structured map of technical concepts and their relationships, it connects a compound to the patents that claim it, the papers that characterize it, and the technology domains it belongs to. That linkage is what turns three separate result sets into one coherent picture.

Agentic workflows then operate on that picture. On an AI-native platform such as Cypris, an agent can assess chemical freedom-to-operate at the claim level, assemble a competitive landscape of a chemical technology, or monitor a compound class continuously, retrieving across patents, papers, and structure data and returning cited output.

Where chemical intelligence is used

Chemical freedom-to-operate is a primary use. Chemical FTO assesses whether making, using, or selling a compound or formulation would infringe active patent claims, and it depends on retrieving claims that may describe the same chemistry in different terms. Competitive monitoring is another: teams track competitor chemical patents and pipelines continuously rather than rebuilding a picture each quarter.

Materials and formulation scouting is a third. Researchers use chemical intelligence to identify sustainable material alternatives, track new synthesis trends, and find who is active in a compound class, drawing on patents and literature together. Each of these questions is answered more completely when structure, patent, and literature evidence is unified.

Chemical intelligence in practice

Cypris is an AI-native R&D intelligence platform that unifies chemical evidence across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology, alongside chemical compound data. The ontology links compounds to the patents that claim them and the papers that characterize them, so semantic search retrieves across all of it rather than one silo.

Cypris Q, the platform's agentic layer, runs chemical FTO, landscape, and prior art workflows and returns cited output, while Agentic Monitoring tracks compound classes and competitor chemical activity continuously across patents, scientific literature, chemical compound data, and regulatory sources. Cypris operates under enterprise API partnerships with OpenAI, Anthropic, and Google, with enterprise-grade security, and serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, and other regulated industries.

Each compound page in our directory shows a slice of these connections: who is patenting, which classifications cluster, which research groups are active. You can browse it freely here.

FAQ

What is a chemical intelligence platform?

A chemical intelligence platform unifies patents, scientific literature, and chemical structure data so R&D teams can search all three together rather than in separate silos. It connects a compound to the patents that claim it and the papers that characterize it, which is broader than chemical patent search alone.

What data does chemical intelligence cover?

Chemical intelligence covers patents and published applications, peer-reviewed papers and preprints, chemical compound and structure data, synthesis and reaction information, and regulatory and commercial signals. The defining feature is that the same compound is linked across every source in which it appears.

Can I search patents and chemical structures together?

Searching patents and chemical structures together requires a platform that unifies both in one corpus and links compounds to the filings that claim them. An AI-powered chemical intelligence platform does this with semantic search and an R&D ontology, so a compound and its patent coverage are connected rather than searched separately.

Is there a platform to search scientific papers and chemical structures?

A chemical intelligence platform searches scientific papers and chemical structures together by unifying literature and compound data in a single corpus. This matters because a compound's properties are often reported in papers before or alongside its appearance in patents, so searching both together gives a fuller picture.

How does AI improve chemical patent research?

AI improves chemical patent research by applying semantic search, which retrieves filings that describe the same compound or reaction in different names and notations. Combined with an R&D ontology that links compounds to their patents and papers, it surfaces evidence that keyword search across a single database misses.

What is chemical freedom-to-operate (FTO)?

Chemical freedom-to-operate assesses whether making, using, or selling a compound or formulation would infringe active patent claims. It depends on retrieving claims that may describe the same chemistry in different terms, which is why semantic search across a unified corpus is central to reliable chemical FTO.

How do R&D teams monitor competitor chemical patents?

R&D teams monitor competitor chemical patents most effectively with continuous, AI-powered monitoring that interprets new filings in the context of a compound class or technology domain. This replaces quarterly manual rebuilds and surfaces competitor chemical activity as it publishes.

Can chemical intelligence track new material synthesis trends?

Chemical intelligence can track new material synthesis trends by analyzing patents and scientific literature together and grouping activity by technical concept. This reveals where synthesis routes and material classes are developing, and which organizations are active, earlier than a patent-only view.

How does semantic search work for chemistry?

Semantic search for chemistry retrieves patents and papers by the meaning of a compound, reaction, or property rather than exact keywords. Because chemistry is described under many names and notations, semantic retrieval surfaces relevant disclosures that literal term matching overlooks.

What is the best chemical intelligence platform for R&D teams?

The best chemical intelligence platform unifies patents, scientific literature, and chemical structure data with semantic search and citable output. Cypris runs chemical intelligence on a corpus of more than 500 million patents and scientific papers organized through a proprietary R&D ontology, alongside chemical compound data, linking compounds to their patents and publications.

‍